-
Biologics or small molecule drugs for rare disease treatment? It is a question
PharmaSources/Miling
July 31, 2019
To both patients and pharmaceutical practitioners, it is a question as to whether to choose biologics or small molecule drugs for rare disease treatment, since the prices are sky-high.
-
GenScript Biotech Opens Biologics R&D and Production Center
contractpharma
July 22, 2019
Meets all U.S., EU and Chinese GMP requirements.
-
Astellas, Seattle Genetics Announce BLA Submission for Enfortumab Vedotin
americanpharmaceuticalreview
July 17, 2019
Astellas Pharma and Seattle Genetics announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the ...
-
WuXi Biologics Plans to Further Expand New Bioconjugation Center
contractpharma
June 24, 2019
To include commercial manufacturing in Wuxi City, China.
-
AGC Biologics Appoints New Chief Technical Officer
contractpharma
June 12, 2019
Kasper Møller most recently served as site head for AGC’s Copenhagen facility.
-
WuXi Biologics Inks Strategic LOI with Global Vax Leader
contractpharma
May 29, 2019
WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
-
SGS Opens Biologics Testing Facility in UK
contractpharma
May 29, 2019
Receives Scottish Enterprise grant of £1.7 million, as a contribution towards the company’s £7.6 million investment.
-
Jacobs to Provide Construction for WuXi Biologics Biomfg. Facility
contractpharma
May 29, 2019
Plant to be WuXi's first outside of China and largest using single-use bioreactors in Ireland.
-
Creating a modern landscape
europeanpharmaceuticalreview
May 17, 2019
There are many business challenges to developing a biologics drug, one of which is effective data management.
-
WuXi Biologics Completes First FDA Routine GMP Inspection
contractpharma
May 16, 2019
Production of Trogarzo is now approved at the Wuxi facility.